All lobbying filings

THE MCMANUS GROUP

THE MCMANUS GROUP filed a Q3 report for ARDELYX on October 20, 2026, reporting $60,000 in lobbying income.

Lobbying for ARDELYX · BioPharma Company

All filings by THE MCMANUS GROUP · Everything ARDELYX has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Issues related to the 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-105-F), specifically the inclusion of oral-only drugs in the ESRD PPS Bundled Payment. Issues related to Most Favored Nation Drug Pricing Reform

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.